Astellas Pharma EBIT

The latest EBIT for ALPMY is $590B as of September 2026. That compares with $230B in the prior-year period — up 151.6% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Astellas Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALPMY's EBIT moved from $230B to $590B — a 151.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Astellas Pharma's operating scale or balance-sheet position.

Against Healthcare companies, ALPMY currently prints $590B for EBIT, while the sector average sits near $1.9T. That is roughly 69.7% below the sector mean. Large gaps often invite a closer look at Astellas Pharma's growth, margins, and balance sheet.

A EBIT figure of $590B for ALPMY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting ALPMY's EBIT ($590B), review year-over-year change from $230B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.